Reemergence of Mycoplasma pneumoniae disease: Pathogenesis and new approaches
Microbial Pathogenesis · 2024-11 · 196 · 106944
DOI: 10.1016/j.micpath.2024.106944 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Microbial Pathogenesis, 2024-11. Verfasst von Hamed Tahmasebi und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Shahroud University of Medical Sciences, Semnan, Iran. Hauptthemen laut MEDLINE: Pneumonia, Mycoplasma, Mycoplasma pneumoniae, COVID-19. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 68 Literaturangaben.
Abstract (Originalsprache)
The review discusses the recurrence of Mycoplasma pneumoniae (M. pneumoniae), a bacterium causing atypical pneumonia, primarily affecting Europe and Asia due to climate change, immunity decline, antibiotic resistance, and genetic heterogeneity. The COVID-19 pandemic initially reduced M. pneumoniae cases due to preventative measures, but its reemergence suggests different transmission dynamics and exacerbates clinical severity with co-infections with other viruses. The pathogenicity of M. pneumoniae is attributed to its intracellular changes, toxin release, and adhesion processes, which can result in a variety of symptoms and problems. Antibiotics and immunomodulators are used in treatment, and attempts are being made to create vaccines. Effective management of its reappearance necessitates surveillance and preventative measures, especially in the context of co-infections and potential outbreaks. M. pneumoniae's resurgence highlights its reliance on a polarized cytoskeletal architecture for host cell attachment and pathogenicity through cytoadherence and cytotoxic agent synthesis. M. pneumoniae has returned even though the COVID-19 pandemic originally reduced incidence; this might be because of things like declining immunity and particular pathogenic characteristics. Meteorological factors like temperature and humidity, along with air quality, including pollutants like PM2.5 and NO2, increase susceptibility to environmental hazards. During the pandemic, non-pharmaceutical measures decreased transmission but did not eradicate the infection. Epidemics typically occur three to five years apart, emphasizing the need for ongoing study and observation. Antimicrobial resistance is a serious issue, necessitating caution and alternative therapies, especially in macrolides. COVID-19 pandemic lessons, such as mask use and hand hygiene, may help limit M. pneumoniae transmission.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Shahroud University of Medical Sciences, Semnan, Iran.
- Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran.
- Department of Immunology, School of Medicine, Semnan University of Medical Sciences, Semnan, Iran.
- Department of Bacteriology and Virology, Semnan University of Medical Sciences, Semnan, Iran. Electronic address: M.eslami@semums.ac.ir.
Zitieren
APA
Tahmasebi, H., Babaeizad, A., Mohammadlou, M., Alibabaei, F., Banihashemian, S. Z., & Eslami, M. (2024). Reemergence of Mycoplasma pneumoniae disease: Pathogenesis and new approaches. Microbial Pathogenesis, 196, 106944. https://doi.org/10.1016/j.micpath.2024.106944
Vancouver
Tahmasebi H, Babaeizad A, Mohammadlou M, Alibabaei F, Banihashemian SZ, Eslami M. Reemergence of Mycoplasma pneumoniae disease: Pathogenesis and new approaches. Microbial Pathogenesis. 2024;196:106944. doi:10.1016/j.micpath.2024.106944
BibTeX
@article{Tahmasebi2024,
author = {Tahmasebi, Hamed and Babaeizad, Ali and Mohammadlou, Maryam and Alibabaei, Farnaz and Banihashemian, Seyedeh Zahra and Eslami, Majid},
title = {Reemergence of Mycoplasma pneumoniae disease: Pathogenesis and new approaches},
journal = {Microbial Pathogenesis},
year = {2024},
volume = {196},
pages = {106944},
doi = {10.1016/j.micpath.2024.106944}
}
EUVIMED